Click here for an archive of Cramer's "Mad Money" recaps.

America's favorite pastime could get bigger than ever, Jim Cramer told Mad Money viewers Monday. And that's why he said

Topps

( TOPP) could be your most valuable player.

"You may not like the baseball card business, but it's worth more than nothing," he said, but the company "is so cheap, so undervalued, that almost any catalyst could give it a bump."

That's why the maker of baseball cards and Bazooka gum is a value play and a play on the start of baseball season.

Cramer believes that the stock could see $10 or $11 from its current level between $8 and $9. Plus, he sees only about $1 of downside, a risk/reward ratio that he likes.

In addition, Cramer said that the company has a beautiful balance sheet that includes $90 million in cash and no debt.

So while the company's 2006 earnings may barely cover its dividend, he believes that its balance sheet means that Topps will be fine.

He also sees upside in the company's candy business, which he said is undervalued.

Money for Nothing

Cramer also said it can be a good idea to buy a company "that does nothing, that contributes nothing to society," and that's

Iconix Brand Group

(ICON) - Get Report

.

This is a brand management company that buys clothing brands, outsources production and then takes a percentage of sales, and its brands include Joe Boxer and Bongo.

Image placeholder title

The company borrows money to finance its acquisitions, and the return on every investment is very high, he said.

However, debt is built into this particular business model, he added, so it's time to "see no debt evil."

Iconix has over $100 million in debt on its balance sheet.

But the company "is in no danger of going belly up," because they're making the maximum amount of money with the lowest down payments.

The company also just acquired Mudd and Mossimo brands, and Wall Street approved by boosting the stock.

Cramer said these are good acquisitions because Mudd is a play on youth retail and Mossimo has an exclusive deal with

Target

(TGT) - Get Report

.

"You read the headlines, you know that immigration ... is the great issue right now," Cramer said. But whether we restrict or open our borders, when it comes to making money just buy

First Data

(FDC) - Get Report

, the company that owns

Western Union

.

That's because immigrants, legal or not, often, send home remittances, Cramer said, adding that immigrants from Latin America and the Caribbean sent home about $40 billion last year.

The company raked in $1.3 billion in earnings on $4 billion of revenue.

First Data controls about 15% of the world's remittance business, a big market chunk, he said. And even though the company's China and India business is still a small part of that business, those markets are growing at 60%, he added.

However, First Data is not just a pure play on wiring money. The company also does money transfers and bill payment, ATM processing and check verification, and it has a credit card business.

That's "too many entangled businesses," he said.

But they're spinning off Western Union in September or October, and Cramer believes that this is "giving Wall Street exactly what it wants."

The spinoff will allow the most profitable portion of the business, Western Union, to be fairly valued against competitors such as

Moneygram

(MGI) - Get Report

and

Global Payments

(GPN) - Get Report

.

And compared with the competition, Cramer believes that Western Union is a steal.

About three weeks ago, Cramer recommended a company called

Sirna Therapeutics

( RNAI), a biotech company that develops therapeutics based on RNA interference (RNAi) technology.

The company announced Monday a deal with

GlaxoSmithKline

(GSK) - Get Report

, and President and CEO Howard Robin joined Cramer to talk about what the deal means for shareholders.

Robin said the deal would not only improve efforts to treat asthma and chronic pulmonary disease by pairing Sirna's technology with GlaxoSmithKline treatments, but also it would mean significant royalties and milestone payments for his company.

However, the CEO said that these milestone payments will be stretched out over time between now and when drugs are approved further down the line.

Robin also said that the market for asthma treatments is growing very fast and is very competitive. But he said the company's technology can be used in a diverse array of treatments, so it is not solely tied to asthma.

To view Cramer's interview with Robin, click here.

Lightning Round

Bullish

Cramer was bullish on

Vasco Data Security International

(VDSI)

,

Cytyc

( CYTC),

Penn National Gaming

(PENN) - Get Report

,

Procter & Gamble

(PG) - Get Report

,

Bed Bath & Beyond

(BBBY) - Get Report

,

Rite Aid

(RAD) - Get Report

,

Dow Chemical

(DOW) - Get Report

and

Marvell Tech

(MRVL) - Get Report

.

Bearish

Cramer was bearish on

Nasdaq Stock Market

I:IXIC

,

Amylin Pharmaceuticals

( AMLN),

Avon

(AVP) - Get Report

,

Doral Financial

(DRL)

ViroPharma

(VPHM)

and

Benetton Group

(BNG)

.

For more of Cramer's insights during the most recent Lightning Round, click here.

Want more Cramer? Check out Jim's rules and commandments for investing from his latest book by

clicking here

.

At the time of publication, Cramer was long Procter & Gamble.

Jim Cramer, host of the CNBC television program "Mad Money," is a Markets Commentator for TheStreet.com, Inc., and CNBC, and a director and co-founder of TheStreet.com. All opinions expressed by Mr. Cramer on Mad Money are his own and do not reflect the opinions of TheStreet.com or its affiliates, or CNBC, NBC UNIVERSAL or their parent company or affiliates. Mr. Cramer's opinions are based upon information he considers to be reliable, but neither TheStreet.com, nor CNBC, nor either of their affiliates and/or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. Mr. Cramer's statements are based on his opinions at the time statements are made, and are subject to change without notice. No part of Mr. Cramer's compensation from CNBC or TheStreet.com is related to the specific opinions expressed by him on "Mad Money."

None of the information contained in "Mad Money" constitutes a recommendation by Mr. Cramer, TheStreet.com or CNBC that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the program. Mr. Cramer's past results are not necessarily indicative of future performance. Neither Mr. Cramer, nor TheStreet.com, nor CNBC guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the program. The strategy or investments discussed may fluctuate in price or value and you may get back less than you invested. Before acting on any information contained in the program, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.

Some of the stocks mentioned by Mr. Cramer on "Mad Money" are held in Mr. Cramer's Action Alerts PLUS Portfolio. The Action Alerts PLUS Portfolio contains all of Mr. Cramer's personal investments in publicly-traded equity securities only, and does not include any mutual fund holdings or other institutionally managed assets, private equity investments, or his holdings in TheStreet.com, Inc. Since March 2005, the Action Alerts PLUS Portfolio has been held by a Trust, the realized profits from which have been pledged to charity. Mr. Cramer retains full investment discretion with respect to all securities contained in the Trust. Mr. Cramer is subject to certain trading restrictions, and must hold all securities in the Action Alerts PLUS Portfolio for at least one month, and is not permitted to buy or sell any security he has spoken about on television or on his radio program for five days following the broadcast.